Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma

Yuan Quan Yu, Liang Wang, Yun Jin, Jia Le Zhou, Yan Hua Geng, Xing Jin, Xiao Xiao Zhang, Jun Jie Yang, Cheng Ming Qian, Dong Er Zhou, Da Ren Liu, Shu You Peng, Yan Luo, Lei Zheng, Jiang Tao Li

Research output: Contribution to journalArticle

Abstract

Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The aim of this study is to identify serologic biomarkers for predicting MVI preoperatively to help facilitate treatment decisions. We used the sero-proteomic approach to identify antigens that induce corresponding antibody responses either specifically in the serum from MVI (+) patients or from MVI (-) patients. Six antigens were subsequently identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin by mass spectrometry. The antibodies titers in sera corresponding to four of these six antigens were measured by ELISA and compared between 35 MVI (+) patients and 26 MVI (-) patients. The titers of anti-HSP 70 antibodies were significantly higher in MVI (-) patients than those in MVI (+) patients; and the titers of anti-Eno-1 antibodies were significantly lower in MVI (-) patients than those in MVI (+) patients. The results were subjected to multivariate analysis together with other clinicopathologic factors, suggesting that antibodies against HSP 70 and Eno-1 in sera are potential biomarkers for predicting MVI in HCC prior to surgical resection. These biomarkers should be further investigated as potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)16362-16371
Number of pages10
JournalOncotarget
Volume7
Issue number13
DOIs
StatePublished - Mar 29 2016

Fingerprint

Hepatocellular Carcinoma
Biomarkers
Antibodies
Antigens
Glutathione Synthase
Serum
Annexin A2
Phosphopyruvate Hydratase
Proteomics
Antibody Formation
Actins
Mass Spectrometry
Therapeutics
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Recurrence
Survival

Keywords

  • Biomarker
  • Diagnosis
  • Hepatocellular carcinoma
  • Microvascular invasion
  • Sero-proteomics

ASJC Scopus subject areas

  • Oncology

Cite this

Yu, Y. Q., Wang, L., Jin, Y., Zhou, J. L., Geng, Y. H., Jin, X., ... Li, J. T. (2016). Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. Oncotarget, 7(13), 16362-16371. https://doi.org/10.18632/oncotarget.7649

Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. / Yu, Yuan Quan; Wang, Liang; Jin, Yun; Zhou, Jia Le; Geng, Yan Hua; Jin, Xing; Zhang, Xiao Xiao; Yang, Jun Jie; Qian, Cheng Ming; Zhou, Dong Er; Liu, Da Ren; Peng, Shu You; Luo, Yan; Zheng, Lei; Li, Jiang Tao.

In: Oncotarget, Vol. 7, No. 13, 29.03.2016, p. 16362-16371.

Research output: Contribution to journalArticle

Yu, YQ, Wang, L, Jin, Y, Zhou, JL, Geng, YH, Jin, X, Zhang, XX, Yang, JJ, Qian, CM, Zhou, DE, Liu, DR, Peng, SY, Luo, Y, Zheng, L & Li, JT 2016, 'Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma', Oncotarget, vol. 7, no. 13, pp. 16362-16371. https://doi.org/10.18632/oncotarget.7649
Yu, Yuan Quan ; Wang, Liang ; Jin, Yun ; Zhou, Jia Le ; Geng, Yan Hua ; Jin, Xing ; Zhang, Xiao Xiao ; Yang, Jun Jie ; Qian, Cheng Ming ; Zhou, Dong Er ; Liu, Da Ren ; Peng, Shu You ; Luo, Yan ; Zheng, Lei ; Li, Jiang Tao. / Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 13. pp. 16362-16371.
@article{ccce034f744d415e9af6153dea78fe3d,
title = "Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma",
abstract = "Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The aim of this study is to identify serologic biomarkers for predicting MVI preoperatively to help facilitate treatment decisions. We used the sero-proteomic approach to identify antigens that induce corresponding antibody responses either specifically in the serum from MVI (+) patients or from MVI (-) patients. Six antigens were subsequently identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin by mass spectrometry. The antibodies titers in sera corresponding to four of these six antigens were measured by ELISA and compared between 35 MVI (+) patients and 26 MVI (-) patients. The titers of anti-HSP 70 antibodies were significantly higher in MVI (-) patients than those in MVI (+) patients; and the titers of anti-Eno-1 antibodies were significantly lower in MVI (-) patients than those in MVI (+) patients. The results were subjected to multivariate analysis together with other clinicopathologic factors, suggesting that antibodies against HSP 70 and Eno-1 in sera are potential biomarkers for predicting MVI in HCC prior to surgical resection. These biomarkers should be further investigated as potential therapeutic targets.",
keywords = "Biomarker, Diagnosis, Hepatocellular carcinoma, Microvascular invasion, Sero-proteomics",
author = "Yu, {Yuan Quan} and Liang Wang and Yun Jin and Zhou, {Jia Le} and Geng, {Yan Hua} and Xing Jin and Zhang, {Xiao Xiao} and Yang, {Jun Jie} and Qian, {Cheng Ming} and Zhou, {Dong Er} and Liu, {Da Ren} and Peng, {Shu You} and Yan Luo and Lei Zheng and Li, {Jiang Tao}",
year = "2016",
month = "3",
day = "29",
doi = "10.18632/oncotarget.7649",
language = "English (US)",
volume = "7",
pages = "16362--16371",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "13",

}

TY - JOUR

T1 - Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma

AU - Yu, Yuan Quan

AU - Wang, Liang

AU - Jin, Yun

AU - Zhou, Jia Le

AU - Geng, Yan Hua

AU - Jin, Xing

AU - Zhang, Xiao Xiao

AU - Yang, Jun Jie

AU - Qian, Cheng Ming

AU - Zhou, Dong Er

AU - Liu, Da Ren

AU - Peng, Shu You

AU - Luo, Yan

AU - Zheng, Lei

AU - Li, Jiang Tao

PY - 2016/3/29

Y1 - 2016/3/29

N2 - Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The aim of this study is to identify serologic biomarkers for predicting MVI preoperatively to help facilitate treatment decisions. We used the sero-proteomic approach to identify antigens that induce corresponding antibody responses either specifically in the serum from MVI (+) patients or from MVI (-) patients. Six antigens were subsequently identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin by mass spectrometry. The antibodies titers in sera corresponding to four of these six antigens were measured by ELISA and compared between 35 MVI (+) patients and 26 MVI (-) patients. The titers of anti-HSP 70 antibodies were significantly higher in MVI (-) patients than those in MVI (+) patients; and the titers of anti-Eno-1 antibodies were significantly lower in MVI (-) patients than those in MVI (+) patients. The results were subjected to multivariate analysis together with other clinicopathologic factors, suggesting that antibodies against HSP 70 and Eno-1 in sera are potential biomarkers for predicting MVI in HCC prior to surgical resection. These biomarkers should be further investigated as potential therapeutic targets.

AB - Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The aim of this study is to identify serologic biomarkers for predicting MVI preoperatively to help facilitate treatment decisions. We used the sero-proteomic approach to identify antigens that induce corresponding antibody responses either specifically in the serum from MVI (+) patients or from MVI (-) patients. Six antigens were subsequently identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin by mass spectrometry. The antibodies titers in sera corresponding to four of these six antigens were measured by ELISA and compared between 35 MVI (+) patients and 26 MVI (-) patients. The titers of anti-HSP 70 antibodies were significantly higher in MVI (-) patients than those in MVI (+) patients; and the titers of anti-Eno-1 antibodies were significantly lower in MVI (-) patients than those in MVI (+) patients. The results were subjected to multivariate analysis together with other clinicopathologic factors, suggesting that antibodies against HSP 70 and Eno-1 in sera are potential biomarkers for predicting MVI in HCC prior to surgical resection. These biomarkers should be further investigated as potential therapeutic targets.

KW - Biomarker

KW - Diagnosis

KW - Hepatocellular carcinoma

KW - Microvascular invasion

KW - Sero-proteomics

UR - http://www.scopus.com/inward/record.url?scp=84971659625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971659625&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7649

DO - 10.18632/oncotarget.7649

M3 - Article

VL - 7

SP - 16362

EP - 16371

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -